Funding Details
- Awarder
- Inbox
- Date Award
- January 21, 2015
- Vertical
- Gene Therapy
- Funding URL
- View Funding Page
- Funding Amount:
-
$30,000,000
Company Info
- Organizations Involved
- Baxter Healthcare, Fondazione Telethon, Audentes Therapeutics, Lysogene, Esteve, AveXis, AAVLife, Voyager Therapeutics
- Founders
- Ken Mills
- Company Description
- REGENXBIO develops adeno-associated viral vector-based therapeutics and research tools, offering NAV, a recombinant AAV-vector.
- Market
- Severe diseases with serious unmet needs
- Location
-
Washington,
DC,
United States
- Coinvestors
- Brookside Capital, Deerfield Management Company, L.P., FoxKiser, Venrock
Links